BCL11A and hematopoietic and lymphoid system neoplasm: Gene editing seems to show promising prospects in the treatment of blood diseases related to BCL11A, but how to avoid the possible adverse effects on other cells after editing is worth considering; in particular, some clinical trials have shown serious adverse effects from gene therapy, including blood cancers, liver toxicity and even death [101,127,128].